Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 12/20 | 0.63 |
| ▸ | CTSL | P07711 | 8/20 | 0.63 |
| ▸ | CTSB | P07858 | 3/20 | 0.48 |
| ▸ | REN | P00797 | 2/20 | 0.44 |
| ▸ | CTSK | P43235 | 2/20 | 0.41 |
| ▸ | MMP1 | P03956 | 3/20 | 0.40 |
| ▸ | MMP2 | P08253 | 3/20 | 0.40 |
| ▸ | MMP3 | P08254 | 3/20 | 0.40 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.39 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.39 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.39 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.39 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.39 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7044867 | 0.88 | CTSS (0.48) | CTSSCTSLCTSBRENCTSK | |
| SCHEMBL7109606 | 0.88 | CTSS (0.48) | CTSSCTSLCTSBRENCTSK | |
| SCHEMBL7045971 | 0.88 | CTSS (0.64) | CTSSCTSLCTSB | |
| SCHEMBL7047934 | 0.86 | CTSS (0.46) | CTSSCTSLCTSBRENCTSK | |
| SCHEMBL7046904 | 0.85 | CTSS (0.45) | CTSSCTSLCTSBRENCTSK | |
| SCHEMBL7049025 | 0.85 | CTSS (0.64) | CTSSCTSLCTSBRENCTSK | |
| SCHEMBL6464156 | 0.84 | CTSS (0.43) | CTSSCTSLCTSBRENMMP1 | |
| SCHEMBL7047088 | 0.84 | CTSS (0.62) | CTSSCTSLCTSBRENCTSK | |
| SCHEMBL7049437 | 0.83 | CTSS (0.51) | CTSSCTSLCTSBRENCTSK | |
| SCHEMBL7048372 | 0.81 | FPR2 (0.52) | CTSSCTSLCTSBRENMMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-6576630-B1 | Alkanoyl substituted benzooxazoles or naphthooxazoles | AXYS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | CTSS 9/4885CTSL 18/4885CTSB 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.